What are the factors and advantages of the EMEA (Europe, Middle East and Africa) Eye Drug Market? Know all the trends, analysis and forecasts 2017-2022

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Units), revenue (Million USD), market share and growth rate of Eye Drug for these regions, from 2017-2022(forecast)
Europe: Germany, France, UK, Russia, Italy and Benelux;
Middle East: Saudi Arabia, Israel, UAE and Iran;
Africa: South Africa, Nigeria, Egypt and Algeria.

Download sample pages of this report: https://goo.gl/rKNPUv

EMEA Eye Drug market competition by top manufacturers/players, with Eye Drug volume (K Units), price (USD/Unit), revenue (Million USD) and market share for each manufacturer/player; the top players including
Pfizer
Novartis
bausch Lomb
Laboratoire Riva
Jamp Pharma
Fresenius
Teva Pharmaceutical?
SANDOZ
Greenstone
Mylan
GE Medical
Mint Pharmaceuticals
Laboratoires Thea
Taj Pharmaceuticals
Actavis
APOTEX
Sun Pharma

There are several methods of achieving therapeutic drug concentrations within the eye and its surrounding structures. By far the most common is topical administration but, when higher concentrations of the drug are required, local injection or systemic administration is considered. Prescription and/or administration of the latter is most commonly initiated in the Eye Clinic, with the exception of a few conditions – eg, suspected cases of giant cell arteritis.

India’s largest drug maker Sun Pharmaceutical Industries Ltd’s drug Seciera, indicated for the treatment of dry eye disease, has displayed positive results in a 12-week multicentre phase-3 clinical trial conducted on 744 patients, the company said in a stock exchange filing on Wednesday.

Seciera is a patented, novel, proprietary nanomicellar formulation containing 0.09% cyclosporine A in a clear, preservative-free, aqueous solution. Seciera is being developed by Ocular Technologies, a company that Sun Pharma recently acquired from Auven Therapeutics for an upfront payment of $40 million.

Following the acquisition, Sun Pharma owns exclusive, worldwide rights for commercialisation of the product and will make certain milestone and royalty payments to Auven.

The advanced randomized, double-masked, vehicle controlled phase-3 confirmatory study showed that Seciera met the primary and key secondary end points and the adverse events reported in the trial were mild to moderate in nature and similar to other approved drugs in the category, Sun Pharma said.

“We are happy to see the early onset of action and strong efficacy results for Seciera. We look forward to discussing these results with US FDA (US Food and Drug Administration) and agree on next steps for the program,” Dilip Shanghvi, managing director, Sun Pharma, was quoted as saying in the filing.Dry eye disease, as defined by the National Health Institute (NHI), occurs when the eye does not produce tears properly, or when the tears are not of the correct consistency and evaporate too quickly. The market for dry eye drugs is expected to reach $5 billion by 2017-2022.

Download sample pages of this report: https://goo.gl/rKNPUv

About Us:
Key Market Insights is a stand-alone organization with a solid history of advancing and exchanging market research reports and logical surveys delivered by our numerous transnational accomplices, which incorporate both huge multinationals and littler, more expert concerns.

Contact:

Mr.mannan
sales@kminsights.com
+1 (888) 278-7681

Leave a Reply

Your email address will not be published. Required fields are marked *

*

seven + six =